FDA Confirms Evidence of Insertional Oncogenesis in Two Zolgensma Cases, Reviews Labeling and Long-Term Follow-Up
Tumor reports now have more specific molecular evidence: in two cases, the treatment vector was found integrated near or within the GLI1 oncogene. The FDA is assessing whether safety labeling and follow-up studies are adequate, and is extending its risk assessment to Itvisma, which uses the same vector.